hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival-Reference-Cited by-同舟云学术

hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival

Published:2018-04-05 Issue:14 Volume:131 Page:1532-1544
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Pellicano Francesca¹,Park Laura¹,Hopcroft Lisa E. M.¹^ORCID,Shah Mansi M.¹,Jackson Lorna¹^ORCID,Scott Mary T.¹^ORCID,Clarke Cassie J.¹^ORCID,Sinclair Amy¹,Abraham Sheela A.¹^ORCID,Hair Alan¹,Helgason G. Vignir¹^ORCID,Aspinall-O’Dea Mark²,Bhatia Ravi³,Leone Gustavo⁴,Kranc Kamil R.⁵^ORCID,Whetton Anthony D.²^ORCID,Holyoake Tessa L.¹

Affiliation:

1. Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom;

2. Stem Cell and Leukaemia Proteomics Laboratory, Faculty Institute of Cancer Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom;

3. Division of Hematology and Oncology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL;

4. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; and

5. MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom

Abstract

Key Points hsa-mir183/EGR1/E2F1 is a novel and critical factor for CML SPC survival. E2F1 plays a pivotal role in regulating CML SPC proliferation status.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/14/1532/1405864/blood783845.pdf

Reference58 articles.

1. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells;Druker;Nat Med,1996

2. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment;Bhatia;Blood,2003

3. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial;Mahon;Lancet Oncol,2010

4. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro;Graham;Blood,2002

5. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group study;Chen;Blood,2012

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia;Science Translational Medicine;2024-06-12

2. circFAM193B interaction with PRMT6 regulates AML leukemia stem cells chemoresistance through altering the oxidative metabolism and lipid peroxidation;Leukemia;2024-02-29

3. Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease;Nature Communications;2024-01-22

4. miR-181a plays the tumor-suppressor role in chronic myeloid leukemia CD34 + cells partially via SERPINE1;Cellular and Molecular Life Sciences;2023-12-16

5. Dysregulation of MiRNA Expression in Patients With Chronic Myelogenous Leukemia At Diagnosis: A Systematic Review;Biomarkers in Medicine;2023-12